RxDoctor Payments Data

Ana Sauceda, MD

Dermatology · San Antonio, TXNPI 1497764302

Payments from drug & device makers

$33,887in general payments, 2019–2025

Across 289 payments — averaging $117.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$26K
  • Johnson & Johnson$2K
  • AbbVie$1K
  • Lilly USA, LLC$955
  • Sanofi$598
  • Novartis$459
  • plus $3K from 25 others

What the payments were for

  • Speaking & faculty fees$24,40072%
  • Food & beverage$8,80826%
  • Education$6782%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,887 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$283,269
Medicare patients
761
Services billed
5,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab192$750,378
Cosentyx Unoready PenSecukinumab74$637,075
OtezlaApremilast48$231,883
Humira(Cf) PenAdalimumab16$193,902
TremfyaGuselkumab12$164,832
Taltz AutoinjectorIxekizumab22$149,991
Cosentyx Sensoready (2 Pens)Secukinumab12$88,948
AdbryTralokinumab-Ldrm11$42,298
OpzeluraRuxolitinib Phosphate11$22,273
Clobetasol Propionate56$2,623
Metronidazole27$1,820
Fluorouracil20$1,324
Ketoconazole76$1,272
Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox12$1,200
Doxycycline Hyclate30$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$395$231,88348 claims
Johnson & JohnsonTremfya$1,612$164,83212 claims
LEO Pharma Inc.Adbry$286$42,29811 claims
Incyte CorporationOpzelura$104$22,27311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,098 dermatology providers in Texas.

Other dermatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →